Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
MRNA

MRNA - Moderna Inc Stock Price, Fair Value and News

141.00USD-4.23 (-2.91%)Market Closed as of 14 Jun 2024, 09:54 am ET

Market Summary

MRNA
USD141.00-4.23
Market Closedas of 14 Jun 2024, 09:54 am
-2.91%

MRNA Alerts

  • 4 major insider sales recently.
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

MRNA Stock Price

View Fullscreen

MRNA RSI Chart

MRNA Valuation

Market Cap

55.6B

Price/Earnings (Trailing)

-9.32

Price/Sales (Trailing)

8.12

EV/EBITDA

-12.02

Price/Free Cashflow

-15.15

MRNA Price/Sales (Trailing)

MRNA Profitability

EBT Margin

-70.12%

Return on Equity

-46.56%

Return on Assets

-35.67%

Free Cashflow Yield

-6.6%

MRNA Fundamentals

MRNA Revenue

Revenue (TTM)

6.8B

Rev. Growth (Yr)

-44.71%

Rev. Growth (Qtr)

53.52%

MRNA Earnings

Earnings (TTM)

-6.0B

Earnings Growth (Yr)

-1.6K%

Earnings Growth (Qtr)

-641.47%

Breaking Down MRNA Revenue

52 Week Range

117.11145.48
(Low)(High)

Last 7 days

-6.2%

Last 30 days

13.1%

Last 90 days

39.8%

Trailing 12 Months

15.1%

How does MRNA drawdown profile look like?

MRNA Financial Health

Current Ratio

4.03

MRNA Investor Care

Shares Dilution (1Y)

0.53%

Diluted EPS (TTM)

-15.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202315.1B10.7B9.1B6.8B
202222.6B23.0B21.4B19.3B
20212.7B7.0B11.8B18.5B
202052.2M106.1M246.1M803.0M
2019122.1M106.3M81.6M60.2M
2018204.5M192.3M191.6M135.1M
2017132.8M157.1M181.5M205.8M
2016000108.4M

Tracking the Latest Insider Buys and Sells of Moderna Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 11, 2024
afeyan noubar
sold
-25,227,400
148
-170,069
-
Jun 11, 2024
afeyan noubar
sold
-4,859,940
148
-32,763
-
Jun 10, 2024
klinger shannon thyme
sold
-766,785
148
-5,178
chief legal officer
Jun 07, 2024
klinger shannon thyme
acquired
-
-
10,247
chief legal officer
Jun 05, 2024
afeyan noubar
sold
-2,268,800
151
-15,000
-
Jun 03, 2024
klinger shannon thyme
sold
-17,167
140
-122
chief legal officer
Jun 03, 2024
hoge stephen
sold
-47,704
140
-339
president
Jun 03, 2024
mock james m
sold
-97,237
140
-691
chief financial officer
May 31, 2024
klinger shannon thyme
acquired
-
-
232
chief legal officer
May 31, 2024
mock james m
acquired
-
-
1,326
chief financial officer

1–10 of 50

Which funds bought or sold MRNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
49.89
31,312
78,550
0.01%
Jun 10, 2024
Hamilton Wealth, LLC
reduced
-52.5
-3,526,020
3,654,370
1.14%
Jun 04, 2024
DekaBank Deutsche Girozentrale
added
14.28
5,534,000
24,697,000
0.05%
May 30, 2024
CAMBRIDGE TRUST CO
unchanged
-
2,375
35,591
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
added
13.71
5,197,000
28,993,000
0.26%
May 24, 2024
Cetera Investment Advisers
added
584
6,293,480
7,287,580
0.02%
May 23, 2024
Wellington Shields & Co., LLC
added
144
892,547
1,469,950
0.26%
May 21, 2024
Atria Investments, Inc
new
-
1,063,040
1,063,040
0.01%
May 21, 2024
APEIRON CAPITAL Ltd
reduced
-77.34
-2,349,570
753,273
0.38%
May 21, 2024
LRI Investments, LLC
new
-
123,823
123,823
0.03%

1–10 of 40

Are Funds Buying or Selling MRNA?

Are funds buying MRNA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MRNA
No. of Funds

Unveiling Moderna Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2024
vanguard group inc
10.20%
39,036,765
SC 13G/A
Feb 13, 2024
vanguard group inc
8.89%
33,906,974
SC 13G/A
Feb 07, 2024
bancel stephane
7.8%
30,384,866
SC 13G/A
Jan 29, 2024
blackrock inc.
6.6%
25,301,057
SC 13G/A
Jan 29, 2024
baillie gifford & co
11.97%
45,654,527
SC 13G/A
Feb 10, 2023
bancel stephane
7.41%
29,151,802
SC 13G/A
Feb 09, 2023
vanguard group inc
7.10%
27,282,173
SC 13G/A
Feb 01, 2023
blackrock inc.
6.8%
26,115,224
SC 13G/A
Jan 19, 2023
baillie gifford & co
11.66%
44,786,746
SC 13G/A
Feb 14, 2022
bancel stephane
7.64%
31,538,184
SC 13G/A

Recent SEC filings of Moderna Inc

View All Filings
Date Filed Form Type Document
Jun 12, 2024
144
Notice of Insider Sale Intent
Jun 11, 2024
144
Notice of Insider Sale Intent
Jun 11, 2024
144
Notice of Insider Sale Intent
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 10, 2024
144
Notice of Insider Sale Intent
Jun 07, 2024
4
Insider Trading
Jun 05, 2024
144
Notice of Insider Sale Intent
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading

Peers (Alternatives to Moderna Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
55.6B
6.8B
13.11% 15.14%
-9.32
8.12
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.2B
2.0B
8.19% -19.39%
-60.96
10.11
75.20% 68.82%
16.0B
2.5B
5.74% -10.79%
77.85
6.47
13.74% 186.89%
14.1B
3.8B
9.90% 2.05%
18.88
3.74
8.58% 129.81%
MID-CAP
5.4B
107.9M
0.17% 71.70%
-9.93
48.09
54.84% -28.31%
5.2B
524.1M
3.28% -53.81%
-12.38
9.86
394.93% 39.61%
3.4B
251.0M
-6.27% -10.41%
-11.62
13.72
73.58% -86.73%
3.3B
240.7M
15.67% -25.01%
-6.96
12.77
-1.03% -213.92%
2.5B
813.8M
1.62% -37.45%
-1.5K
3.06
56.43% 98.83%
2.1B
996.6M
11.65% 94.95%
-5.3
2.12
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-7.16% 29.42%
27.77
4.4
60.38% -34.49%
564.4M
881.7K
22.84% 567.64%
-16.72
481.06
-77.61% 33.36%
244.6M
4.2M
-17.34% 57.33%
-1.96
58.8
-66.30% 48.24%
22.1M
2.1M
36.17% 271.01%
-0.95
7.61
-13.45% 69.54%

Moderna Inc News

Latest updates
MarketWatch17 hours ago
Yahoo Finance10 Jun 202409:50 pm
Yahoo Finance17 May 202407:00 am

Moderna Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-100.0%-2,8111,8313441,8625,0843,3644,7496,0667,2114,9694,3541,93757115767.008.0014.0017.0013.0016.00
Costs and Expenses-48.9%1,4332,8053,8432,2112,2283,5042,1982,3021,8391,8011,4111,292671846392189139----
Operating Expenses---------------393188139145148157158
  S&GA Expenses-41.7%27447044233230537527821126820116812177.0079.0048.0037.0024.0026.0028.0028.0027.00
  R&D Expenses-24.4%1,0631,4061,1601,1481,1311,211820710554648521421401759344152115118120128130
EBITDA Margin-Infinity%-0.65*--0.22*0.11*0.36*0.52*0.64*0.70*0.73*0.73*0.66*0.56*0.25*--------
Income Taxes106.8%10.00-1471,672-369-38419017427757254221928339.002.001.00---0.47-0.18-0.32-0.02
Earnings Before Taxes-1764.3%-1,16570.00-1,958-1,749-3051,6551,2172,4744,2295,4103,5523,0631,260-271-232-117-124-123-123-135-132
EBT Margin-21.8%-0.70*-0.58*-0.26*0.08*0.33*0.50*0.62*0.68*0.72*0.72*0.64*0.54*---------
Net Income-641.5%-1,175217-3,630-1,38079.001,4651,0432,1973,6574,8683,3332,7801,221-273-233-117-124-123-123-134-132
Net Income Margin-26.6%-0.87*-0.69*-0.38*0.11*0.32*0.43*0.55*0.61*0.65*0.66*0.60*0.50*---------
Free Cashflow-394.8%-1,185402-1,740-1,149-1,3381,5701632172,6313,1903,1774,033---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-9.2%16,72918,42619,45021,88424,12525,85826,05626,04327,60924,66920,92316,15312,6947,3374,6513,4862,0681,5891,5911,6851,806
  Current Assets-7.0%9,60010,32510,79910,59912,12213,43114,29713,56316,35016,07113,42510,96911,7036,2983,5772,7971,2501,1291,0941,0971,141
    Cash Equivalents-29.4%2,0512,9072,9323,8013,4413,2173,0272,8735,0486,8485,5505,6035,4422,6361,5061,762392248174152503
  Inventory46.0%2952024877157329492,0771,9211,9421,44196564349447.00-------
  Net PPE-------------------204209213
Liabilities-14.4%3,9124,5725,9954,9355,2626,7358,0648,05810,53410,52410,7999,4498,8564,7761,891539427415339347360
  Current Liabilities-21.1%2,3803,0154,3853,1233,4994,9236,8076,8129,2389,1289,9578,8408,4414,3891,474162135143148162159
Shareholder's Equity-7.5%12,81713,85413,45516,94918,86319,12317,99217,98517,07514,14510,1246,7043,8382,5612,7602,9471,6411,1751,2481,3351,442
  Retained Earnings-8.6%12,43113,60613,38917,01918,39918,32016,85515,81213,6159,9585,0901,757-1,023-2,244-1,971-1,737-1,620-1,496-1,369-1,246-1,111
  Additional Paid-In Capital31.3%4873712771937311,1731,4882,4133,6444,2115,0034,9314,8604,8024,7264,6763,2682,6692,6182,5822,557
Shares Outstanding0.3%383382381381386385390396402403404402---------
Float----40,200---48,800---80,800---25,250---3,380-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-259.0%-989622-1,600-915-1,2251,6622523042,7633,3103,2764,0632,9711,264893-24.00-106-99.05-107-108-144
  Share Based Compensation27.8%10179.0077.0074.0075.0062.0070.0050.0044.0037.0040.0035.0030.0026.0022.0025.0020.0020.0021.0021.0018.00
Cashflow From Investing121.9%118-5387891,9442,011-1,048945-1,152-3,921-1,138-3,327-3,878-180-190-1,17913.00-316130113-246-11.76
Cashflow From Financing112.8%14.00-109-58.00-668-542-438-1,041-1,327-642-873-2.00-24.0026.0044.0030.001,38157832.0016.004.000.00
  Buy Backs----1.006285264021,0061,298623857-----------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

MRNA Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Total revenue$ 167$ 1,862
Operating expenses:  
Cost of sales96792
Research and development1,0631,131
Selling, general and administrative274305
Total operating expenses1,4332,228
Loss from operations(1,266)(366)
Interest income120109
Other expense, net(19)(48)
Loss before income taxes(1,165)(305)
Provision for (benefit from) income taxes10(384)
Net (loss) income$ (1,175)$ 79
(Loss) earnings per share:  
Basic (in usd per share)$ (3.07)$ 0.20
Diluted (in usd per share)$ (3.07)$ 0.19
Weighted average common shares used in calculation of (loss) earnings per share:  
Basic (in shares)382386
Diluted (in shares)382405
Net product sales  
Revenue:  
Total revenue$ 167$ 1,828
Other revenue  
Revenue:  
Total revenue$ 0$ 34

MRNA Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 2,051$ 2,907
Investments6,4725,697
Accounts receivable, net137892
Inventory295202
Prepaid expenses and other current assets645627
Total current assets9,60010,325
Investments, non-current3,6384,677
Property, plant and equipment, net2,0631,945
Right-of-use assets, operating leases697713
Deferred tax assets8181
Other non-current assets650685
Total assets16,72918,426
Current liabilities:  
Accounts payable183520
Accrued liabilities1,3961,798
Deferred revenue559568
Income taxes payable5263
Other current liabilities19066
Total current liabilities2,3803,015
Deferred revenue, non-current5883
Operating lease liabilities, non-current637643
Financing lease liabilities, non-current575575
Other non-current liabilities262256
Total liabilities3,9124,572
Commitments and contingencies (Note 11)
Stockholders’ equity:  
Preferred stock, par value $0.0001; 162 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 202300
Common stock, par value $0.0001; 1,600 shares authorized as of March 31, 2024 and December 31, 2023; 383 and 382 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively00
Additional paid-in capital487371
Accumulated other comprehensive loss(101)(123)
Retained earnings12,43113,606
Total stockholders’ equity12,81713,854
Total liabilities and stockholders’ equity$ 16,729$ 18,426
MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration agreement with CARsgen Therapeutics Holdings Limited to evaluate CTO41in combination with mRNA cancer vaccine. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEmodernatx.com
 INDUSTRYBiotechnology
 EMPLOYEES3900

Moderna Inc Frequently Asked Questions


What is the ticker symbol for Moderna Inc? What does MRNA stand for in stocks?

MRNA is the stock ticker symbol of Moderna Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Moderna Inc (MRNA)?

As of Thu Jun 13 2024, market cap of Moderna Inc is 55.62 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRNA stock?

You can check MRNA's fair value in chart for subscribers.

What is the fair value of MRNA stock?

You can check MRNA's fair value in chart for subscribers. The fair value of Moderna Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Moderna Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Moderna Inc a good stock to buy?

The fair value guage provides a quick view whether MRNA is over valued or under valued. Whether Moderna Inc is cheap or expensive depends on the assumptions which impact Moderna Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRNA.

What is Moderna Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, MRNA's PE ratio (Price to Earnings) is -9.32 and Price to Sales (PS) ratio is 8.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRNA PE ratio will change depending on the future growth rate expectations of investors.